Study Stopped
enrollment moved very slowly which was not anticipated, and, funding issues
High Definition White Light Endoscopy and Narrow Band Imaging for the Assessment of Barrett's Disease After Endoscopic Therapy
1 other identifier
observational
21
1 country
1
Brief Summary
The investigators seek to test the hypothesis that the improved version of high definition white light endoscopes and Narrow Band Imaging (NBI) are more accurate in detecting residual Barrett's Metaplasia and Dysplasia disease after previous resection or ablation treatments than current versions of these endoscopes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2011
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2011
CompletedFirst Submitted
Initial submission to the registry
May 18, 2011
CompletedFirst Posted
Study publicly available on registry
May 26, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2014
CompletedApril 10, 2014
April 1, 2014
3.1 years
May 18, 2011
April 8, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
Accuracy of Agreement Between Imaging and Histology
The accuracy of agreement between endoscopic imaging diagnosis compared with biopsy histology diagnosis.
9 months
Secondary Outcomes (1)
Presence of Residual Disease
9 months
Eligibility Criteria
Men and women (not pregnant) presenting to the GI Lab for Upper Endoscopy. Child-bearing potential not excluded.
You may qualify if:
- Age 18 years and older
- Patients with Barrett's esophagus (BE) dysplasia as the original indication for treatment
- Undergoing any type of endoscopic BE resection or ablation treatment including RFA, cryotherapy, photodynamic therapy, or EMR, or combinations of these.
- \<1cm of circumferential, peninsular, or island-type BE on prior endoscopy or ablation
- Ability to provide written, informed consent
- Deferral Criteria: This category is for patients in two specific situations, 1) Erosive esophagitis, and, 2) presence of a nodule suspicious for the presence of neoplasia.
- Erosive esophagitis: patients found to have erosive esophagitis, will be deferred for up to 3 months from their Index study procedure, to permit more aggressive medical therapy to heal the erosive esophagitis. After healing, the Index study procedure will be performed up to 3 months later, and the follow-up endoscopy (and study closure) performed 3 to 6 months after that (total of no more than 9 months).
- Presence of nodule suspicious for neoplasia: for patients found to have such nodular lesions, the Index study procedure will be deferred for 3 months, while Endoscopic Mucosal Resection is performed and subsequently heals.
- Note: Only one deferral per patient is permitted, and this one deferral is allowed only for these specific criteria. The end of the study will be defined by the time of follow-up of the last patient who was not deferred; any deferred patients who have not completed follow-up procedures by that time, may miss their follow-up visit as part of the study. (This is to prevent the possibility of delaying the close of the study due to deferral of a procedure late in the study.)
You may not qualify if:
- Current participation in another clinical study
- Complete eradication of BE documented by biopsies in 3 or more previous endoscopic procedures performed after resection/ablation
- Inability to obtain biopsies due to anticoagulation, varices, etc.
- Pregnancy
- Worse than Grade C erosive esophagitis
- Less than 3 weeks from previous endoscopy with biopsy or 6 weeks from previous endoscopic therapy (ablation or resection).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
- Olympuscollaborator
Study Sites (1)
Mayo Clinic
Jacksonville, Florida, 32224, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Herbert C. Wolfsen,, M.D.
Mayo Clinic
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Medicine, Mayo College of Medicine; Director of Endoscopy, Mayo Clinic Florida
Study Record Dates
First Submitted
May 18, 2011
First Posted
May 26, 2011
Study Start
February 1, 2011
Primary Completion
March 1, 2014
Study Completion
March 1, 2014
Last Updated
April 10, 2014
Record last verified: 2014-04